Back

Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Highlights from the Young on cutting edge therapy for lowering lipids Lipid-Lowering Agents ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

4 More presentations in this session

Presentation thumbnail
Impact of ACLY on type 2 diabetes in UK Biobank: A Mendelian randomisation study
Doctor A. Stiby (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Lipid testing trends before and after hospitalization for myocardial infarction among adults in the U.S., 2008-2019
Ms C. Wiener (Durham, US)
Abstract Slides Video
Presentation thumbnail
The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients
Doctor I. Bytyci (Pristina, XK)
Abstract Slides Video
Presentation thumbnail
Acute arterial events across all vascular territories in the FOURIER trial
Doctor K. Oyama (Sendai, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Highlights from the Young on cutting edge therapy for lowering lipids

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources